Zacks Small Cap Research on MSN
EDSA: Gearing up to initiate phase 2 vitiligo trial in mid-2026
EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Gearing Up for Phase 2 Vitiligo Trial in Mid-2026 Edesa Biotech, Inc.
The authors provide a useful integrated analytical approach to investigating MASLD focused on diverse multiomic integration methods. The strength of evidence for this new resource is solid, as ...
Golden Cross Resources (TSXV: AUX) (OTCQB: ZCRMF) (FSE: ZMLO) (“Golden Cross” or the “Company”) is pleased to provide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback